That morning, Barclays changed its recommendation on Illumina stock to underweight (read: sell) from the previous equal weight (hold). It also pulled the lever on a significant price target decrease, ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

On Friday, Nasdaq Inc’s (NASDAQ:NDAQ) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens on December 23. Illumina, Inc. (NASDAQ:ILMN) was removed from the ...

Fintel reports that on December 22, 2025, Canaccord Genuity maintained coverage of Illumina (NasdaqGS:ILMN) with a Hold ...

Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Shares of Illumina (ILMN) are down about 2% after the biotechnology company reported mixed third-quarter financial results. Illumina announced earnings per share (EPS) of $1.14, which was well ahead ...

HSBC downgraded shares of Illumina (NASDAQ:ILMN – Free Report) from a buy rating to a hold rating in a research report sent to investors on Friday morning, MarketBeat Ratings reports. The brokerage ...

Learn more about whether Charles River Laboratories International, Inc. or Illumina, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics ...

Illumina (NASDAQ:ILMN – Free Report) had its price objective cut by Canaccord Genuity Group from $145.00 to $135.00 in a report published on Friday,Benzinga reports. They currently have a hold rating ...

China placed Illumina on its unreliable entities list. Being placed on the unreliable entities list, opens the company up to sanctions from the Chinese government. Up Next: Get 5 Dark Horse Stocks ...